July 30, 2018
Shareholders in Israeli pharmaceutical company Kitov Pharmaceuticals asked a New York federal judge on Friday to approve a $2 million deal to settle allegations the company and its CEO falsified late-stage trial results for a hypertension treatment and forced stocks to drop.
March 21, 2018
A New York federal judge on Tuesday dismissed investors' claims against the chief financial officer of an Israel-based pharmaceutical company but said the company and its CEO are still on the line for allegedly misleading investors about falsified late-stage trial results for a hypertension treatment.
August 03, 2017
An Israel-based pharmaceutical company urged a New York federal judge Wednesday to toss a proposed class action alleging it falsified late-stage trial results for a hypertension treatment and subsequently caused the company's share price to drop, saying the investors haven’t sufficiently demonstrated how the purported falsification occurred.
June 15, 2017
The Rosen Law Firm has agreed to withdraw its application to steer a potential New York stock-drop class accusing an Israeli drug company of securities fraud after the defense said its representation of a competing California class in a similar case was a conflict, an order docketed Wednesday says.
May 22, 2017
An Israeli drug company accused of securities fraud told a New York federal judge Friday that the Rosen Law Firm shouldn't be allowed to represent investors in the case because it represents a competing class of shareholders in a similar case.
February 08, 2017
Kitov Pharmaceuticals Holdings Ltd. investors hit the Israel-based company with a suit in New York federal court on Tuesday over a stock drop that allegedly occurred once news broke that its CEO was detained on suspicion of publishing misleading information about drug testing.